首页> 外文期刊>Herz >Update on heart failure
【24h】

Update on heart failure

机译:关于心力衰竭的更新

获取原文
获取原文并翻译 | 示例
           

摘要

Heart failure is one of the leading diseases in internal medicine worldwide. Because of the increase in population aging, the incidence and prevalence of heart insufficiency is rising annually and is now the most frequent individual diagnosis among hospitalized patients in Germany. The mortality rate has recently been reduced, since new pharmacological options, especially the inhibition of neprilysin, have been developed; however, heart failure is still associated with a high mortality and morbidity rate. Thus, guideline-conform treatment is of crucial importance. This review highlights and summarizes the current scientific knowledge on heart failure from 2017 and 2018 based on the guidelines of the European Society of Cardiology. New aspects about heart failure with middle grade limitations of ejection fraction are firstly presented. Subsequently, innovative diagnostic and therapeutic strategies, new pharmacological developments and handling of frequent comorbidities in patients with heart failure are discussed.
机译:心力衰竭是全球内科的主要疾病之一。由于人口衰老的增加,心脏不足的发病率和患病率每年都在上升,现在是德国住院患者的最常见的个体诊断。最近已经减少了死亡率,因为已经开发了新的药理学选择,特别是抑制内尿液的抑制;然而,心力衰竭仍然与高死亡率和发病率有关。因此,指导符合性治疗至关重要。本综述亮点并总结了目前2017年和2018年对心力衰竭的科学知识,基于欧洲心脏病学会的指导方针。首先介绍了与射出分数中级局限性的心力衰竭的新方面。随后,讨论了创新的诊断和治疗策略,新的药理发展和心力衰竭患者常见的伴有的常规糖化性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号